Huang Hung-Yu, Lo Chun-Yu, Yang Lan-Yan, Chung Fu-Tsai, Sheng Te-Fang, Lin Horng-Chyuan, Lin Chang-Wei, Huang Yu-Chen, Chang Chee-Jen, Chung Kian Fan, Wang Chun-Hua
Division of Pulmonary and Critical Care, Department of Internal Medicine, Saint Paul's Hospital, Taoyuan 330, Taiwan.
Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei 105, Taiwan.
J Clin Med. 2019 Apr 25;8(4):562. doi: 10.3390/jcm8040562.
Negative pressure ventilation (NPV), when used as an adjuvant to pulmonary rehabilitation, improves lung function, increases exercise capacity, and reduces exacerbations. The aim of this study was to determine whether maintenance NPV improves long-term clinical outcomes and reduces mortality in patients with chronic obstructive pulmonary disease (COPD). Between 2003 and 2009, 341 patients were treated for COPD either with or without hospital-based NPV. We measured forced expiratory volume in one second (FEV), 6-min walking distance (6MWD), and oxygen saturation by pulse oximetry (SpO) during a 6-min walk test (6MWT) every 3-6 months. Desaturation (D) during the 6MWT was defined as a reduction in SpO of ≥10% from baseline. The NPV group had a better survival outcome than the Non-NPV group. The 8-year survival probabilities for the NPV and Non-NPV groups were 60% and 20%, respectively ( < 0.01). Baseline desaturation was a significant risk factor for death, and the risk of death increased with desaturation severity (SpO 80~89: hazard ratios (HR) 2.7, 95% confidence interval (CI) 1.4-5.3; SpO < 80: HR 3.1, 95% CI 1.3-7.4). The NPV group had a slower decline in lung function and 6MWD. The NPV + D and Non-NPV+D had a threefold and fourfold increase in the risks of all-cause mortality compared with the NPV-ND, respectively. Maintenance non-invasive NPV reduced long-term mortality in COPD patients. The desaturating COPD patients had an increased mortality risk compared with non-desaturating COPD patients.
负压通气(NPV)作为肺康复的辅助手段时,可改善肺功能、提高运动能力并减少病情加重。本研究的目的是确定维持性NPV是否能改善慢性阻塞性肺疾病(COPD)患者的长期临床结局并降低死亡率。在2003年至2009年期间,341例COPD患者接受了基于医院的NPV治疗或未接受该治疗。我们每3至6个月在6分钟步行试验(6MWT)期间测量一秒用力呼气量(FEV)、6分钟步行距离(6MWD)以及通过脉搏血氧饱和度仪测定的血氧饱和度(SpO)。6MWT期间的血氧饱和度下降(D)定义为SpO较基线降低≥10%。NPV组的生存结局优于非NPV组。NPV组和非NPV组的8年生存概率分别为60%和20%(P<0.01)。基线血氧饱和度下降是死亡的一个重要危险因素,且死亡风险随血氧饱和度下降严重程度增加(SpO 80~89:风险比(HR)2.7,95%置信区间(CI)1.4 - 5.3;SpO<80:HR 3.1,95%CI 1.3 - 7.4)。NPV组的肺功能和6MWD下降较慢。与NPV无血氧饱和度下降组相比,NPV伴血氧饱和度下降组和非NPV伴血氧饱和度下降组的全因死亡风险分别增加了三倍和四倍。维持性无创NPV可降低COPD患者的长期死亡率。与无血氧饱和度下降的COPD患者相比,有血氧饱和度下降的COPD患者死亡风险增加。